The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 21, 2015

Filed:

Sep. 17, 2013
Applicant:

The J. David Gladstone Institutes, San Francisco, CA (US);

Inventors:

Erik D. Roberson, Vestavia Hills, AL (US);

Lennart Mucke, San Francisco, CA (US);

Assignee:

THE J. DAVID GLADSTONE INSTITUTES, San Francisco, CA (US);

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); G01N 33/50 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); C12N 15/113 (2013.01); G01N 33/5023 (2013.01); G01N 33/5058 (2013.01); G01N 33/5088 (2013.01); G01N 33/6896 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); G01N 2800/28 (2013.01); G01N 2800/2821 (2013.01);
Abstract

Agents that reduce the level of a tau gene product in a cell, e.g., in a neuron, include antisense nucleic acids. For example, antisense nucleic acids can be used to down-regulate expression of a tau gene in a cell (e.g., in a neuron). The antisense sequence is complementary to the mRNA of the targeted gene (e.g., tau), and inhibits expression of the targeted gene products. Suitable oligonucleotides can be chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which modifications alter the chemistry of the backbone, sugars, or heterocyclic bases.


Find Patent Forward Citations

Loading…